SYShauna H. Yuan

Shauna H. Yuan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shauna H. Yuan has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Music therapy interest in patients with Alzheimer's disease and Alzheimer's disease related dementia: A survey study

    by Laura Hemmy, Andrea Cevasco-Trotter, Michael Silverman, Sonya Wang, Shauna H. Yuan

    Background: Music therapy can be an effective psychosocial intervention for people with Alzheimer's disease (AD) and Alzheimer's disease related dementia (ADRD). However, there is a lack of literature regarding people with AD and ADRD's interest in music therapy. Objective: The purpose of this study was to examine interest in music therapy among patients receiving care at an outpatient memory clinic. Methods: A total of 70 patients receiving outpatient services at a university memory clinic completed a researcher-designed one-page survey assessing demographic information and interest in music therapy. Clinic staff recruited participants at check-in for their regularly scheduled appointments. Results: Participants were a mean 74.4 years old (SD = 9.5 years). Most participants identified as White (90%), had access to reliable internet (89.7%), and had not previously heard of music therapy (56.7%). Participants indicated they would prefer individual music therapy (58.2%) over group music therapy (10.9%). Participants tended to have low interest levels when asked to rate their interest in receiving music therapy in both in-person or teletherapy formats. Conclusions: Although music therapy can help maintain cognitive abilities in older adults, participants receiving care in our outpatient memory clinic expressed low interest in receiving music therapy in person or via telehealth. However, many participants were unfamiliar with music therapy, underscoring the need for education and advocacy to increase awareness and access to care. Implications, limitations, and suggestions for future research are provided.

  • Open Access

    Integrative multiomics reveals common endotypes across PSEN1, PSEN2, and APP mutations in familial Alzheimer’s disease

    by Phoebe Valdes, Andrew B. Caldwell, Qing Liu, Michael Q. Fitzgerald, Srinivasan Ramachandran, Celeste M. Karch, Douglas R. Galasko, Shauna H. Yuan, Steven L. Wagner, Shankar Subramaniam

    Background: PSEN1, PSEN2, and APP mutations cause Alzheimer’s disease (AD) with an early age at onset (AAO) and progressive cognitive decline. PSEN1 mutations are more common and generally have an earlier AAO; however, certain PSEN1 mutations cause a later AAO, similar to those observed in PSEN2 and APP. Methods: We examined whether common disease endotypes exist across these mutations with a later AAO (~ 55 years) using hiPSC-derived neurons from familial Alzheimer’s disease (FAD) patients harboring mutations in PSEN1 A79V , PSEN2 N141I , and APP V717I and mechanistically characterized by integrating RNA-seq and ATAC-seq. Results: We identified common disease endotypes, such as dedifferentiation, dysregulation of synaptic signaling, repression of mitochondrial function and metabolism, and inflammation. We ascertained the master transcriptional regulators associated with these endotypes, including REST, ASCL1, and ZIC family members (activation), and NRF1 (repression). Conclusions: FAD mutations share common regulatory changes within endotypes with varying severity, resulting in reversion to a less-differentiated state. The regulatory mechanisms described offer potential targets for therapeutic interventions.


  • Open Access

    Ten Reasons Why Neurologists Should Refer Patients With Alzheimer Dementia to Music Therapy

    by Shauna H. Yuan, Michael J. Silverman, Andrea M. Cevasco-Trotter, Sonya G. Wang

    Alzheimer dementia (AD) constitutes a major societal problem with devastating neuropsychiatric involvement. Pharmaceutical interventions carry a heightened risk of side effects; thus, nonpharmacological interventions such as music-based interventions (MBIs), including music therapy, are recommended. The 2023 Neurology release of the Music Based Intervention Toolkit for Brain Disorders of Aging showcased music's emerging role as an intervention to manage symptoms of various brain disorders while defining the building blocks of MBIs to guide research in the exploration of music's therapeutic potential. This study extends beyond the research aspects of the MBI Toolkit to clinical applications by providing neurologists with a summary of MBIs, the MBI Toolkit, how board-certified music therapists (MT-BCs) administered music therapy is a unique MBI, and 10 reasons why they should make referrals to music therapy for their patients with AD.


  • Open Access

    A high efficiency precision genome editing method with CRISPR in iPSCs

    by Avinash Singh, G. Dalton Smedley, Jamee-Grace Rose, Kristina Fredriksen, Ying Zhang, Ling Li, Shauna H. Yuan

    The use of genetic engineering to generate point mutations in induced pluripotent stem cells (iPSCs) is essential for studying a specific genetic effect in an isogenic background. We demonstrate that a combination of p53 inhibition and pro-survival small molecules achieves a homologous recombination rate higher than 90% using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) in human iPSCs. Our protocol reduces the effort and time required to create isogenic lines.


  • Open Access

    CRISPR/Cas9-Based Protocol for Precise Genome Editing in Induced Pluripotent Stem Cells

    by Avinash Singh, Swathy Babu, Marcus Phan, Shauna Yuan

    The advent of clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-based genome editing has marked a significant advancement in genetic engineering technology. However, the editing of induced pluripotent stem cells (iPSCs) with CRISPR presents notable challenges in ensuring cell survival and achieving high editing efficiency. These challenges become even more complex when considering the specific target site. P53 activation as a result of traditional CRISPR editing can lead to apoptosis, potentially worsening cell health or even resulting in cell death. Mitigating this apoptotic response can enhance cell survival post-CRISPR editing, which will ultimately increase editing efficiency. In our study, we observed that combining p53 inhibition with pro-survival small molecules yields a homologous recombination rate of over 90% when using CRISPR in human iPSCs. This protocol significantly streamlines the editing process and reduces the time and resources necessary for creating isogenic lines.


  • Open Access

    A narrative review of music therapy for neuropsychiatric symptoms in Alzheimer’s disease and rationale for protocolized music teletherapy

    by Sonya G. Wang, Andrea M. Cevasco-Trotter, Michael J. Silverman, Shauna H. Yuan

    Introduction: Alzheimer’s Disease (AD) constitutes a major societal problem with devastating neuropsychiatric involvement in over 90% of those diagnosed. The large spectrum of AD neuropsychiatric symptoms leads to polypharmacological prescribing that, in turn, poses a major risk for increased side effects. Non-pharmacological interventions such as music therapy (MT) are therefore recommended as first-line treatments. The amalgamation of an aging population, long lifespan, and shortage of qualified music therapists limits access to MT services for AD.Objective: The purpose of this paper is to provide a rationale for a protocolized music teletherapy (MTT) intervention to increase accessibility for MT as a psychosocial intervention for neuropsychiatric symptoms in people with AD by conducting a narrative review of the existing MT and AD literature.Methods: We conducted a narrative review of MT and MTT publications indexed in PubMed and Google Scholar wherein authors used the Neuropsychiatric Inventory. We examined the impact of MT on neuropsychiatric symptoms of AD and identified MTT as a way to increase access to clinical services.Results: MT can have positive impacts on neuropsychiatric symptoms in AD. However, we identified an ensuing need for protocolized MT interventions, access to services, and increased awareness. MTT is an option that can address these needs.Discussion: Although MT can have positive effects on neuropsychiatric symptoms and can be beneficial and safe for individuals with AD, the current approach to MT practice is enormously heterogeneous with studies demonstrating variable therapist qualifications, uses of music, therapy approaches, and clinical populations. Congruently, the existing literature indicates that MT has not been standardized with protocolized interventions, making it difficult for clinicians and researchers to objectively assess the evidence, and thus, prescribe MT interventions. The lack of MT standardization, coupled with a low number of music therapists relative to people with AD, result in a lack of awareness that hinders access to MT as a psychosocial treatment for neuropsychiatric symptoms in people with AD. We therefore propose that protocolized MTT interventions are needed to increase access to better address neuropsychiatric symptoms associated with AD.


  • Open Access

    Integrative multiomics reveals common endotypes across PSEN1, PSEN2, and APP mutations in familial Alzheimer’s disease

    by Phoebe Valdes, Andrew B Caldwell, Qing Liu, Michael Q Fitzgerald, Srinivasan Ramachandran, Celeste M Karch, Dominantly Inherited Alzheimer Network (Dian), Douglas R Galasko, Shuana H Yuan, Steven L Wagner, et al.

    Background Mutations in PSEN1, PSEN2, and APP can lead to Alzheimer’s disease (AD) with an early age at onset (AAO) and hallmark progressive cognitive decline. These mutations are highly penetrant. Although mutations in PSEN1 are more common and usually have an earlier AAO, certain mutations in PSEN1 cause a later AAO, similar to PSEN2 and APP mutations. We sought to determine whether common disease endotypes exist across these mutations with a relatively late AAO. Methods We generated hiPSC-derived neurons from patients harboring autosomal-dominant, familial Alzheimer’s disease (FAD) mutations in PSEN1, PSEN2, and APP with a documented age at onset (AAO) around 55 years: PSEN1A79V, PSEN2N141I, and APPV717I. We carried out RNA-seq and ATAC-seq to mechanistically characterize the gene expression and chromatin accessibility changes, respectively. Differential expression analysis, enrichment analysis, TF activity identification, and co-expression module detection were performed for RNA-seq. Differential peak analysis and annotation, TF motif footprinting and differential motif accessibility, and peak functional enrichment were performed for ATAC-seq. This approach allowed us to identify the correlation between gene expression and chromatin accessibility associated with key disease endotypes. Results Using a multiomics approach, we identify and characterize common endotypes in mutations across all three FAD genes: dedifferentiation of a mature neuron to a less differentiated quasi-neuron state, dysregulation of synaptic signaling, repression of mitochondrial function and metabolism, and inflammation. The integrativeanalysis allowed us to ascertain the master transcriptional regulators associated with these endotypes, including REST, ASCL1, and ZIC family members (activation), as well as NRF1 (repression). Conclusions Our findings characterize the common regulatory changes within endotypes across these FAD mutations. However, the severity of dysregulation often differs between PSEN1, PSEN2, and APP mutations both in magnitude and direction. The overarching common link between mutations in FAD genes is the reversion to a less-differentiated neuron state. The transcriptional regulatory mechanisms described within disease endotypes offer potential targets for therapeutic interventions.


  • Open Access

    Endotype reversal as a novel strategy for screening drugs targeting familial Alzheimer's disease

    by Andrew B. Caldwell, Qing Liu, Can Zhang, Gary P. Schroth, Douglas R. Galasko, Kevin D. Rynearson, Rudolph E. Tanzi, Shauna H. Yuan, Steven L. Wagner, Shankar Subramaniam

    While amyloid‐β (Aβ) plaques are considered a hallmark of Alzheimer's disease, clinical trials focused on targeting gamma secretase, an enzyme involved in aberrant Aβ peptide production, have not led to amelioration of AD symptoms or synaptic dysregulation. Screening strategies based on mechanistic, multi‐omics approaches that go beyond pathological readouts can aid in the evaluation of therapeutics. Using early‐onset Alzheimer's (EOFAD) disease patient lineage PSEN1A246E iPSC‐derived neurons, we performed RNA‐seq to characterize AD‐associated endotypes, which are in turn used as a screening evaluation metric for two gamma secretase drugs, the inhibitor Semagacestat and the modulator BPN‐15606. We demonstrate that drug treatment partially restores the neuronal state while concomitantly inhibiting cell cycle re‐entry and dedifferentiation endotypes to different degrees depending on the mechanism of gamma secretase engagement. Our endotype‐centric screening approach offers a new paradigm by which candidate AD therapeutics can be evaluated for their overall ability to reverse disease endotypes.


  • Top Cited Papers
    Open Access

    Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer’s patients

    by Jerome Mertens, Joseph R. Herdy, Larissa Traxler, Simon T. Schafer, Johannes C.M. Schlachetzki, Lena Böhnke, Dylan A. Reid, Hyungjun Lee, Dina Zangwill, Diana P. Fernandes, et al.